Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is a promising biopharmaceutical company with a single product focused on preventing life-threatening infections in end-stage renal disease patients. With strong potential for growth through contracts and new drug development, the company's success hinges on the approval and market acceptance of DefenCath. While there may be risks and potential challenges in clinical trials and market expansion, strong management and a focus on sustainability bode well for the future of this stock.

Bears say

Cormedix is a high-risk investment due to its heavy reliance on a single product, DefenCath, for most of its revenue. This product also faces potential competition and pricing risks in the future. In addition, the company has recently acquired Melinta, which brings in additional revenue streams but also adds complexity and potential execution risks. Overall, the company is in a vulnerable position with limited diversification and a lot of uncertainties.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.